FacebookXInstagramPinterest

Health News

2 03, 2021

Increased risk of serious heart-related problems and cancer with Tofacitinib

By |2021-03-02T18:35:31+00:00March 2, 2021|Health News|0 Comments

The FDA is alerting the public that preliminary results from a safety clinical trial show an increased risk of serious heart-related problems and cancer with Xeljanz, Xeljanz XR (tofacitinib) compared with tumor necrosis factor inhibitors. The safety trial also investigated other potential risks, including blood clots in the lungs and death, but those results are not yet available.

Read More
The contents of the MedTactics.com, such as text, graphics, images, and other material contained on the Site ("Content") are for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on MedTactics.com!If you think you may have a medical emergency, call your doctor or emergency immediately. MedTactics.com does not recommend or endorse any specific tests, physicians, products, procedures, opinions, or other information that may be mentioned on the Site. Reliance on any information provided by MedTactics.com, Medtactics.com contributors, or other commentators to the Site is solely at your own risk.
FacebookXInstagramPinterest
Go to Top